Not yet recruiting
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
NCT06554028
- Conditions
- Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Hypopharynx Cancer, +12 more
- Locations
-
- Henan Cancer Hospital Zhengzhou, Henan, China